what is known already: Since 1999, the PGD Consortium has collected, analysed and published 12 data sets and an overview of the first 10 years of data collections. study design, size, duration: Data were collected from each participating centre using a FileMaker Pro database (versions 5 -11).
Introduction
The European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium was established in 1997. Its major objectives are to establish guidelines, to promote best practice and to collect data on PGD cycles, pregnancies, deliveries and children. Continued ESHRE PGD Consortium data collection XIII in situ hybridization (FISH)-based testing, amplification-based testing and biopsy) have been written (Harton et al., 2011a,b,c,d) . To date, 12 extensive data collections have been published, covering all applications of PGD, including monogenic diseases, HLA typing and chromosome abnormalities, preimplantation genetic screening (PGS) and social sex selection (Geraedts et al., 1999 (Geraedts et al., , 2000 ESHRE PGD Consortium Steering Committee, 2002; Sermon et al., 2005 Sermon et al., , 2007 Harper et al., 2006 Harper et al., , 2010b Goossens et al., , 2012 Moutou et al., 2014 ). An overview has been presented after 10 years of data collection (Harper et al., 2012) . This 13th report summarizes data collected for the calendar year 2010 and follow-up of pregnancies and babies born until October 2011.
Materials and Methods
Participating centres anonymously reported data on PGD cycles, pregnancies and babies in separate files using a FileMaker Pro database (versions 5 -11) . The blank FileMaker Pro files were distributed to each PGD Consortium member centre at the end of 2009. Submitted data were 'cleaned' by the science manager of ESHRE. This preliminary analysis allowed the identification of omissions and any ambivalent data entries. Records with incomplete data were excluded from the calculations whereas data inconsistencies were clarified following contact with the relevant participating centre. The different files were then assigned to expert co-authors for an in-depth analysis, followed by calculations and presentation of results in tables. Clinical pregnancies were defined as the presence of one or more fetal hearts at 6 weeks of gestation. Implantation rate was defined as the number of fetal hearts per 100 embryos transferred. Delivery rate was defined as the percentage of pregnancies with delivery per oocyte retrieval procedure (OR) and per embryo transfer procedure.
Results
Only data from centres with a full PGD Consortium membership were taken into account, as only these members can provide full information on all aspects of PGD. This report includes data from 62 centres. The results are represented in tables according to an established lay out. Accompanying text is deliberately concise and seven tables are available in an electronic version only: Supplementary Table SIIc lists the abnormal  karyotypes carried by the patients undergoing PGD, Supplementary  Table SIIIc lists the X-linked diseases for which sexing was carried out,  Supplementary Table SIVc lists the monogenic diseases for which PGD  was carried out, Supplementary Tables SVIIIa (data I -XII) and SVIIIb (data XIII) list the complications of pregnancy and Supplementary Tables SXIIa (data I -XII) and SXIIb (data XIII) list the congenital malformations and the neonatal complications. An overview of all cycles collected previously in data collections I -XII can be found in Table Ia , while an overview of the current data collection can be found in Table Ib . The data for social sexing (48 cycles) have not been included in this last table, see below. For all PGD/PGS cycles (5780 cycles to OR), ICSI was the method most often used for fertilization (5192/ 5780, 90%). For all cycles to biopsy (5651), zona pellucida drilling was more commonly performed using a laser (4250/5651, 75%) and cleavage-stage aspiration was the preferential stage/method for biopsy (4526/5651, 80%) ( Table Ib) . Table IIb summarizes the 1071 cycles with OR for data collection XIII, a total number that has increased by 23% compared with data XII (870). In 64 cycles, PGD for a structural chromosome abnormality was performed simultaneously with aneuploidy screening, a slight decrease as compared with data XII. In 15 cycles, PGD was performed simultaneously for an additional FISH (13 cycles) or monogenic indication (2 cycles). Two PGD cycles were performed for a complex chromosomal rearrangement.
PGD cycles for structural chromosomal abnormalities
As for all years (cumulative data shown in Table IIa ), data XIII showed that PGD for reciprocal translocations was performed more often than for any other type of structural chromosome abnormality (60%). For reciprocal translocations, the number of cycles performed for female carriers more or less equalled that for male carriers, whereas for Robertsonian translocations (28% of total cycles), the number of cycles performed for male carriers was about 2-fold that of female carriers. The Robertsonian translocation male carrier group was dominated by the 45,XY,der(13;14) karyotype (61%), an indication that is known to coincide with male infertility (70% of couples in this group).
Overall, 47% of cycles were performed for infertile patients. The rate of infertility ranged from 35% for female carriers up to 70% for male carriers, both in the group with Robertsonian translocations.
Mean female age was 33 years, a figure that shows little variation over the years. In 82% of all cycles to OR, ICSI was used for fertilization, similar to data XII. Nearly all cycles to OR (96%) reached the biopsy stage. The use of laser drilling for zona breaching covered 77% of all cycles in data XIII. Aspiration of blastomeres from cleavage-stage embryos remained the preferred biopsy method (89%). 3  16  2  39  1  4  65   Cleavage aspiration  954  548  1441  1490  323  393  5149   Cleavage extrusion  50  39  83  108  12  19  311   Cleavage flow displacement  2  0  2  4  3  0  11   Blastocyst  2  1  11  10  0  1  25   Embryology   COC's  14 832  8762  22 345  23 640  4560  5611  79 750   Inseminated  12 365  7470  19 027  20 517  3758  4776  67 913   Fertilized  8419  5456  13 568  14 979  2607  3475  48 504   Biopsied  5987  4158  10 308  11 765  1840  2699  36 757   Successfully biopsied  5913  4110  10 171  11 608  1820  2672  36 294   Diagnosed  5413  3805  9458  10 867  1681  2479  33 703   Transferable  2057  1128  1921  2123  740  814  8783   Transferred  1359  795  1532  1691  506  545  6428   Frozen  296  136  141  151  77  99  900 analysed by FISH (93%), while array technology or PCR were applied in a minority of cycles (6 and 1% respectively) . For data XIII, 13 211 oocytes were collected, a mean of 12.3 per cycle. Of these, 61% (8042/13 211) were fertilized (2 pronuclei) and 77% (6209/8042) of the resulting embryos were biopsied. Of the embryos successfully biopsied, 94% (5810/6149) gave a diagnostic result, of which only 24% (1403/5810) were transferable. This was in line with previous years (data I -XII) where a mean of 13.5 oocytes per cycle were collected and 26% of diagnosed embryos were genetically transferable. As expected, the lowest percentage of transferable embryos was found in the reciprocal translocation group (19% for male carriers and 16% for female carriers). Of all transferable embryos, 68% were actually transferred and 18% were frozen.
From 1071 cycles to OR, only 62% resulted in an embryo transfer procedure (ranging from about 49% for female reciprocal translocation carriers to 80% for carriers of a deletion). This is in agreement with previous data (embryo transfer in 64% of cycles to OR; data I -XII 3791/5897) showing that a high level of chromosomally abnormal embryos is found in patients carrying chromosomal abnormalities.
A positive hCG was obtained in 261 cycles, with a positive heart beat in 206 cycles (19% per OR and 31% per embryo transfer). The poorest outcome, 12% positive heart beat per OR, in the group of female reciprocal translocation carriers is a consequence of the lowest percentage of transferable embryos available for this group. Overall, the implantation rate was 26% (246/951), ranging from 22% in the male carrier of a Robertsonian translocation group to 33% in the female carrier of a reciprocal translocation group. Finally, the delivery rate was 15% per OR (165/1071) and 25% per embryo transfer procedure (165/659). There were 10 reported miscarriages and 31 clinical pregnancies were lost to follow-up. Implantation and delivery rates have remained stable over the last years: the delivery rate for data I -XII is 18% per OR and 28% per embryo transfer procedure.
PGD cycles for sexing for X-linked diseases
Tables IIIa and IIIb summarize the 1376 and 108 cycles to OR collected for data collections I -XII and XIII, respectively. As holds true for the PGD cycles for a chromosomal abnormality, the majority of cycles for X-linked diseases in data XIII (Table IIIB) was performed with ICSI (78%; 77/99), laser drilling (80%; 79/99) and biopsy by cleavage-stage aspiration (96%; 95/99). FISH was no longer the only method used for sexing cycles: PCR was applied in 12% of cycles.
For data XIII, 1294 oocytes were collected (a mean of 12.0 per OR), 73% (821/1132) of inseminated oocytes were fertilized and 74% (608/821) of the resulting embryos were biopsied. Of the embryos successfully biopsied, 95% (564/594) gave a diagnostic result, of which only 32% (178/564) were transferable. From 178 transferable embryos, 118 were actually transferred in 80 cycles (74% of cycles to OR). A positive hCG was obtained in 33 cycles, with a positive heart beat in 23 cycles (21% per OR and 29% per embryo transfer). This gave an implantation rate of 23% (27/118). Finally, the delivery rate was 19% per OR (20/108) and 25% per embryo transfer (20/80). There were two reported miscarriages and one pregnancy was lost to follow-up. For data XIII, ICSI was used in the majority of cycles (99% of cycles to OR) and PCR was still the most widely used first-line method of DNA amplification (90% of cycles to PGD). The percentage of cycles relying on whole genome amplification as method of DNA amplification (6% of cycles to PGD) was the same as the previous data collection (6%). Genome-wide array technologies for monogenic disorders have now been introduced in nearly 3% of cycles.
PGD cycles for monogenic diseases
The use of laser was the preferred method for biopsy (75% of cycles to PGD); acidic tyrode or mechanical action was applied in 15 and 10% of cycles to PGD, respectively. These results were very similar to data collection XII. Day 3 cleavage-stage embryo biopsy was most frequently used (93% of cycles to PGD) while the use of blastocyst biopsy remained low (2%). This was in line with previous data collections: 93 and 1% for cleavage-stage and blastocyst biopsy respectively. Genetic testing was carried out on either one blastomere (43% of cycles to PGD) or two blastomeres per embryo (37% of cycles to PGD). In 14% of cycles a mixture of one and two blastomeres was applied. Polar bodies or trophectoderm (TE) cells were used in the remaining 6% of cycles. A total number of 19 941 cumulus-oocyte complexes (COC) were collected and 76% of mature oocytes that were inseminated actually fertilized. A total of 80% of fertilized embryos were biopsied with a 98% success rate. Of the embryos successfully biopsied, 91% gave a diagnostic result, of which 43% were genetically transferable. From 1543 PGD procedures, 81% resulted in an embryo transfer. Per cycle to OR on average 12.7 COCs were collected with 10.4 mature oocytes for insemination. This yielded on average 7.9 fertilized embryos. Per PGD cycle on average 6.4 embryos were suitable for biopsy. Diagnosis was achieved for 5.8 embryos, of which 2.5 embryos were shown to be genetically transferable. On average 1.3 embryos could be transferred while 0.7 embryos were used for cryopreservation, which was very similar to data XII. A positive hCG was obtained in 537 cycles, with a positive heart beat in 446 cycles (28.0% per OR and 36% per embryo transfer) and 522 fetal hearts, giving an overall implantation rate of 27% (522/1954). Finally, the delivery rate was 24% per OR and 31% per embryo transfer; this corresponded with the results from the cumulative data I -XII (23% per OR and 29% per embryo transfer). There were 10% miscarriages and 22 clinical pregnancies were lost to follow-up.
Preimplantation genetic screening
Overall, 2979 PGS cycles were reported in data collection XIII (Table Vb) . This represents a 6% reduction compared with Data XII (3551). The mean age of women undergoing PGS was 39 years. The most common indications for PGS were for women with advanced maternal age (36%), couples who had experienced repeated implantation failure (15%) or recurrent miscarriage (14%) and males with a variety of phenotypes grouped as severe male factor (9%). Other indications were previous abnormal pregnancies, individuals with abnormal karyotypes, including mosaicism for numerical chromosomal abnormalities and couples with more than one indication. A small number of couples underwent PGS following oocyte donation or without a reported medical indication. 144 (73) 67 (66) 187 (62) 170 (49) 12 (80) 36 (71) 43 (73) 659 ( The majority of biopsies (2072/2978, 70%) were at cleavage stage. Laser biopsy was the preferred method (2219/2978, 75%); acidic tyrode's or mechanical zona breaching was applied in 17 and 8% of cycles to PGS, respectively. Only 4% of cycles involved the use of arrays and FISH was used in almost all of the remaining cycles. From a total of 26 166 oocytes that were inseminated, 19 084 (73%) were fertilized. Of 15 068 embryos that were successfully biopsied, 14 548 resulted in a diagnosis (56% of all oocytes inseminated and 96% of all Continued ESHRE PGD Consortium data collection XIII embryos biopsied). Of these 31% were genetically transferrable, 72% were actually transferred and 14% were frozen. This was in accordance with the cumulative data of previous years (Table Va) where 35% of diagnosed embryos were transferable and 74% were used for transfer while 13% were cryopreserved. A positive hCG was obtained in 762 cycles, with a positive heart beat in 594 cycles, yielding a clinical pregnancy rate of 20% per OR or 30% per embryo transfer procedure. This was comparable with the overall clinical pregnancy rates from data I -XII (20% per OR and 28% per embryo transfer). There were 430 reported deliveries, although 39 clinical pregnancies were lost to follow-up. Overall, of 2979 cycles that reached OR, 2012 (68%) had an embryo transfer giving an overall delivery rate of 14% per cycle to OR and 21% per cycle to embryo transfer. The miscarriage rate per clinical pregnancy was 18%, which is not different from the 17% reported in data XII.
PGD cycles for social sexing
The number of reported cycles for social sexing in data XIII was similar to previous data collections, accounting for ,1% (48/5780) of all cycles submitted. There have been 705 cycles for social sexing reported so far (data I-XII) ( Table VIa) . Because social sexing as an indication for PGD is debatable, only the cycle numbers will be included in this and future consortium reports; cycle details will no longer be presented.
Pregnancies and babies
Tables VIIa, VIIb, IXa, IXb, Xa, Xb, XIa, XIb and the Supplementary Tables SVIIIa, SVIIIb, SXIIa and SXIIb summarize the pregnancy and baby data. Data XIII included 1503 pregnancies (Table VIIb) Table SVIIIb ). The delivery rates per indication were reported in Tables IIb, IIIb, IVb and Vb. Caesarean section was performed for 39% of the deliveries (380/982) ( Table IXb) . In 150 cases, the method of delivery was not known. Confirmation of the diagnosis was performed prenatally (251/639) and/or post-natally (388/639) ( Table Xb) . Table Xb and Supplementary Table SXIIb describe the data on congenital malformations, neonatal complications and perinatal deaths as were collected from 601 out of 1152 (52%) babies. It was clear that the organization of adequate children follow-up is more difficult than the follow-up of the pregnancies (only 79/1210 clinical pregnancies were lost to follow-up). Moreover, data indicate that major and minor malformations as well as neonatal complications have been classified differently among centres. A major malformation was reported in 8 singletons and 4 twins out of 601 babies documented; minor malformations were identified in 3 singletons and 3 twins. Several abnormalities were found that were not related to the PGD indication. The number of multiple pregnancies remained high (243/1210, 20%) (Table VIIb) ; this is not different from data XII (22%). Overall, for pregnancies and babies, data XIII was comparable to previous data collections. It should be noted that for data collection X, XI and XII, the total number of children born, as shown in the cumulative Table XIa was not correct. In data XII, the total number should have been 6063 instead of 5063; similarly, in data X and XI, 1000 children were missing in the total number. This error has been corrected in data collection XIII, meaning that the total number of children born after data collection I -XII is 7301, as indicated in Table XIa .
Misdiagnoses
Table XIIIa summarizes the misdiagnoses reported for data I -XII, with no misdiagnoses reported in data X and data XI. In data XIII, three adverse misdiagnoses were reported (Table XIIIb) . One case from a PGD for Fragile X syndrome was identified by prenatal diagnosis. This involved a cycle in which three of the five transferrable embryos had been chosen for transfer. When the patient underwent amniocentesis it was found that the fetus was a female carrier and the pregnancy was terminated. Re-analysis of the first PCR products corresponding to the transferred embryos confirmed the diagnosis obtained in the PGD (one healthy female and two healthy males). Closer examination of other parameters indicated that the embryo transfer in this cycle had been carried out exceptionally by only one embryologist, and it was assumed that a mistake was made during the transfer and a contiguous embryo was picked instead of a correct one. Subsequently, the centre has been very strict about double checks and embryo transfer is Quadruplet to twin 0 4
Triplet to twin 0 11
Triplet to singleton 0 14
Twin to singleton 0 6
Continued 23% for data XII and 21% for data XI. As previously observed, pregnancy rates did not correlate with the number of cycles that each centre performs.
Discussion
This 13th data report of the ESHRE PGD Consortium demonstrates a slight decrease (6%) in the number of PGD cycles, and related pregnancies and babies. This is mainly because of the decline in PGS cycles, which decreased from 3401/5641 (60%) in data XI and 3551/6160 (58%) in data XII to 2979/5780 (52%) in data XIII. In preceding years, the number of PGS cycles had increased annually but by 2010, a number of RCTs had clearly demonstrated that routine PGS using FISH at cleavage stage was not beneficial and a consensus was published by the ESHRE PGD Consortium stating that future studies with alternative biopsy timing and genetic testing were necessary to evaluate the clinical benefit of PGS (Harper et al., 2010a) . For the three cases with a misdiagnosis result reported in data XIII, transfer of the wrong embryo was proposed as most likely cause for one of them. The centre involved strengthened their internal quality control steps as a measure to help preventing further adverse outcomes. Such double control steps are an important factor within a quality management system. Laboratories can implement a quality management system without having an external evaluation but an assessment against international standards by an independent accreditation body has been recommended and even been required in many countries. In 2008, only 33% of 53 European PGD centres had achieved or were preparing for accreditation (Corveleyn et al., 2008) . Results from a survey in 2014 showed an improvement on this, with 56% of 46 IVF units and 50% of 46 diagnostic units in the field of PGD having obtained accreditation according to national standards or international standards (the general quality management standard ISO9001 and ISO15189 which is specific for medical laboratories) (unpublished data).
The other two misdiagnoses reported in data XIII included a trisomy 21 following PGS. In the first case, the pregnancy had ensued from a cycle with FISH on first and second polar bodies, although the information was incomplete for the second polar body. In fact, this is the third case reported to the PGD consortium data collections in which a lack of results from the second polar body leads to a misdiagnosis (Table XIIIa) . For the second trisomy 21 misdiagnosis case, the single cell shown to be euploid after FISH, may have been derived from a chromosomally mosaic euploid/aneuploid embryo. Alternatively, the embryo was truly trisomic, but the single cell analysed was interpreted as euploid because of a technical error that occurred during the FISH procedure.
To date, including all cycles up to data XIII, misdiagnosis has been reported for only 13/9317 PCR-based cycles and 21/34 855 FISHbased PGD cycles. As many embryo transfers have no follow-up (no pregnancy or birth), and only a minority of centres perform audit through re-analysis of untransferred supernumerary embryos, the numbers reported in the data collections may not reflect the true misdiagnosis in PGD. However, a recent multicentre retrospective study, e TOP, termination of pregnancy. One TOP for misdiagnosis of reciprocal translocation, one TOP for Down syndrome following PGD for HLA compatibility, one TOP for complication in pregnancy following PGD for NF1 (NF1, neurofibromatosis type I), two TOPs for ancephalocoele, one TOP for social reasons, one TOP of twin with misdiagnosis for CMT (Charcot-Marie-Tooth disease) 1a, one TOP for 47,XY+13, one TOP for encephelocele and one TOP for 47,XY+21, two TOPs after ultrasound abnormalities, two TOPs for unknown reason and one because of divorce.
f One heterotrophic gestation continued as singleton after reduction of extra-uterine gestation at 6 weeks.
g One triplet resulted in a singleton due to reduction of one fetus and vanishing of another fetus.
h One triplet: fetal reduction, followed by amniocentesis and loss of remaining twin at 16 weeks (1 fetal sac counted in reduction, 2 in miscarriage, 1 second trimester pregnancy loss after miscarriage counted).
i TOP after misdiagnosis : One misdiagnosis for sexing, FISH, female fetus, indication social sexing; one misdiagnosis for A-Thal, PCR; one misdiagnosis for myotonic dystrophy, PCR, one misdiagnosis after PGS, karyotype 45,X; one misdiagnosis for a reciprocal translocation 46,XY,der(15)t(3;15)(q25.1;q26.3). TOP after ultrasound (four): enlarged lateral ventricle, two singletons with cardiopathy, one singleton with tetralogy of Fallot. TOP after amniocentesis, not related to the PGD: trisomy 18, indication for PGD parent carrier of reciprocal translocation not involving chromosome 18; one polymalformation; one cystic hygroma, failed karyotype; one Turner mosaic, one spina bifida, 5 trisomy 21 pregnancies, one mosaic 46,XY/47,XY+18 (misdiagnosis), one Hemivertebrae, hypoplastic cerebellum, hydrocephaly (46,XX), one abnormal chromosome 15, one polycystic kidney, one Finnish nefrosis twin (both affected), one confirms cytomegalovirus infection, one elective termination (unknown cause) and one Hydrocephaly termination of a 8 months pregnancy (started as quadruplet: 2 selective reductions, one miscarriage after chorionic villous sampling (CVS) and the last fetus TOP). j One TOPs for acrania following PGD for CF, one TOP for severe growth retardation following PGD for Fragile X, one TOP for agenesis corpus callosum following PGS for maternal age, one TOP for limb body wall defect following PGS for AS male factor, one TOP for neural tube defect following PGS for male factor, twin TOP for Down syndrome risk following PGS for male factor, one TOP due to malformation at 16 weeks in remaining twin where first twin miscarried at 8 weeks, one misdiagnosis for sexing, PCR, indication Duchenne, twin pregnancy, selective termination of male fetus. Cycle done in 1996, Y-specific amplification only, Two ultrasound abnormalities, one spina bifida and hydrocephaly and one cystic hygroma. TOP of 2 monozygotic fetus of a triplet because of misdiagnosis (AS repeated IVF failures), anamnios, 47,XY,+21, 47,XYY, microdeletion 18, two fetus with trisomy 13. ESHRE PGD Consortium data collection XIII which assessed the validity of PCR-based PGD through reanalysis of untransferred embryos from monogenic-PGD cycles, reassuringly demonstrated the high diagnostic value of PCR-based PGD. Based on reanalysis of almost 1000 embryos from 6 different PGD centres the sensitivity of PCR-based PGD for monogenic diseases was demonstrated to be 99.2% (Dreesen et al., 2014) . The number of cycles has increased annually since the start of the data collection, except for data XIII, where for the first time, a decrease in the total cycle number was reported. Nevertheless, the number of participating centres (62) was still slightly higher than for the previous data collection XII (60). Data submitting is a time consuming activity and the steering committee acknowledges the effort of all contributing centres. Curating the data is time consuming as well, explaining the growing lag in evaluation and publication of data collections. An on-line data ) ; TOP of two fetus of a triplet because of misdiagnosis (unspecified). These two fetus were monozygotic, the third fetus of the triplet was ongoing and resulted in the at term birth of a healthy male (AS repeated IVF failures). Misdiagnosis of 46,XY,der(17)t(5;17)(p13;p13)mat after PGD for reciprocal translocation t(5;17)(p13;p13). Misdiagnosed sex after PGS for maternal age and recurrent miscarriages. Trisomy 21 after PGS for maternal age and recurrent miscarriages. XY, t(11; 22) [7] (FISH reciprocal translocation); Trisomy 21, confirmation after TOP (AS maternal age and repeated IVF failures); 46XX, 16q+ (AS maternal age); Trisomy 15 (AS maternal age); Trisomy 17 (AS recurrent miscarriages); 45,XO (FISH Robertsonian translocation); Trisomy 12 (AS maternal age); Embryo 46,XX, umbilical cord mosaic 47,XX,+14/48,XX,+14,+17 (AS maternal age); 45,XO (FISH reciprocal translocation); Trisomy 8 (AS recurrent miscarriages); Trisomy 21 (AS maternal age); 47,XX,+4 (AS SMF), two times trisomy 7 (twin pregnancy, AS recurrent miscarriages), trisomy 10 (AS maternal age), three times 47,XX,+14 (one twin pregnancy (AS maternal age and recurrent miscarriages), one twin pregnancy of which the karyotyping of the second fetus failed (AS maternal age and recurrent IVF failures), trisomy 16 (AS maternal age and repeated IVF failures), chromosomal abnormality 18 (AS recurrent miscarriages), 47,XY,+20 (AS maternal age), trisomy 21 (reciprocal translocation), 92,XXXX (AS repeated IVF failures), 92,XXYY (AS maternal age and repeated IVF failures); 47,XY+2 after PGD for reciprocal translocation (46,XY,t(8;9)(q21.2;p21). Total 388 1 submission platform is planned for launch in the summer of 2015. It will have built-in data checks and should substantially improve the process of data collection. The new platform will take into account that many PGD cycles are no longer carried out within the timeframe of a single procedure, from OR through to fresh embryo transfer. Alternative strategies have emerged where several hormonal stimulation cycles are planned for oocyte/embryo accumulation and the improved survival rate following (biopsied) embryo vitrification has allowed PGD centres to perform embryo biopsy, testing and embryo transfer in completely separate time frames if necessary. Thus data registration has become more complex, but the new on-line data platform will offer a clear overview of all segments and can be potentially used by all consortium members.
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